-
公开(公告)号：US20240360184A1
公开(公告)日：2024-10-31
申请号：US18768336
申请日：2024-07-10
Applicant: Molecular Templates, Inc.
Inventor： Eric POMA , Erin WILLERT , Garrett Lee ROBINSON , Sangeetha RAJAGOPALAN , Brigitte BRIESCHKE
IPC: C07K14/25 , A61K39/00 , C07K14/245 , C07K16/00 , C07K16/08 , C07K16/10 , C07K16/28 , C07K16/32 , C12N9/10 , C12N9/24 , C12N15/62
CPC classification number: C07K14/25 , C07K14/245 , C07K16/00 , C07K16/085 , C07K16/088 , C07K16/089 , C07K16/1063 , C07K16/286 , C07K16/2863 , C07K16/2866 , C07K16/2887 , C07K16/32 , C12N9/1077 , C12N9/2497 , C12N15/62 , C12Y204/02036 , C12Y302/02022 , A61K2039/6037 , C07K2319/04 , C07K2319/33 , C07K2319/40 , C07K2319/55 , Y02A50/30
Abstract: The present invention relates to Shiga toxin effector polypeptides with reduced antigenic and/or immunogenic potential. Immunogenicity can be a limitation for the repeated administration to mammals of proteins and polypeptides derived from Shiga toxins. The Shiga toxin effector polypeptides of the present invention have uses as components of therapeutics, diagnostics, and immunization materials. The cytotoxic proteins of the present invention have uses for selective killing of specific cell types and as therapeutics for the treatment of a variety of diseases, including cancers, immune disorders, and microbial infections. The proteins of the present invention also have uses for detecting specific cell types, collecting diagnostic information, and monitoring the treatment of a variety of diseases, such as, e.g., cancers, immune disorders, and microbial infections.
-
公开(公告)号：US20240358823A1
公开(公告)日：2024-10-31
申请号：US18434318
申请日：2024-02-06
Applicant: Vaxcyte, Inc.
Inventor： Jeffery C. FAIRMAN , Jon H. HEINRICHS , Wei CHAN
IPC: A61K39/385 , A61K38/00 , A61K39/00 , A61K39/09 , A61P31/04 , C07K14/00 , C07K14/285 , C07K14/33 , C07K14/34
CPC classification number: A61K39/385 , A61K39/092 , A61P31/04 , C07K14/001 , C07K14/285 , C07K14/33 , C07K14/34 , A61K38/00 , A61K2039/6037 , A61K2039/627 , A61K2039/70
Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
-
公开(公告)号：US12097250B2
公开(公告)日：2024-09-24
申请号：US18505504
申请日：2023-11-09
Applicant: Merck Sharp & Dohme LLC
Inventor： William J. Smith , Patrick McHugh , Michael Albert Winters , Julie M. Skinner , Jian He , Luwy Musey , Chitrananda Abeygunawardana , Yadong Adam Cui , Michael J. Kosinski
IPC: A61K39/00 , A61K39/09 , A61K39/116 , A61K39/145 , A61K39/385 , A61K47/02 , A61K47/10 , A61K47/22 , A61P31/04 , A61K9/00
CPC classification number: A61K39/092 , A61K39/116 , A61K39/145 , A61K39/385 , A61K47/02 , A61K47/10 , A61K47/22 , A61P31/04 , A61K9/0019 , A61K2039/54 , A61K2039/545 , A61K2039/55 , A61K2039/55516 , A61K2039/6037 , A61K2039/70
Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.
-
公开(公告)号：US11992521B2
公开(公告)日：2024-05-28
申请号：US18049507
申请日：2022-10-25
Applicant: Merck Sharp & Dohme LLC
Inventor： Patrick Leonard Ahl , Akhilesh Bhambhani , Christopher Jon Farrell , Patrick McHugh , Morrisa C. Jones , Daniel D. Roth , Jessica R. Sinacola , Justin Stanbro , Matthew P. Watson , Emily Wen , Michael A. Winters
CPC classification number: A61K39/092 , A61K47/61 , A61K47/62 , A61K2039/6037 , A61K2039/64 , A61K2039/70
Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.
-
公开(公告)号：US11952406B2
公开(公告)日：2024-04-09
申请号：US18328544
申请日：2023-06-02
Applicant: OTHAIR PROTHENA LIMITED
Inventor： Robin Barbour , Gene Kinney , Wagner Zago , Tarlochan S. Nijjar
CPC classification number: C07K14/4711 , A61K39/0007 , A61K39/39 , A61P25/28 , A61P37/04 , A61K2039/53 , A61K2039/545 , A61K2039/55516 , A61K2039/55544 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , A61K2039/575 , A61K2039/6037 , C07K2319/00
Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.
-
Patent Agency Ranking
公开(公告)号：US11945849B2
公开(公告)日：2024-04-02
申请号：US18328528
申请日：2023-06-02
Applicant: OTHAIR PROTHENA LIMITED
Inventor： Robin Barbour , Gene Kinney , Wagner Zago , Tarlochan S. Nijjar
CPC classification number: C07K14/4711 , A61K39/0007 , A61K39/39 , A61P25/28 , A61P37/04 , A61K2039/53 , A61K2039/545 , A61K2039/55516 , A61K2039/55544 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , A61K2039/575 , A61K2039/6037 , C07K2319/00
Abstract: The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and/or tau, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and/or amyloid-beta accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide.
-
7.发明公开公开(公告)号：US20240066109A1
公开(公告)日：2024-02-29
申请号：US18270043
申请日：2021-12-29
Applicant: VaxNewMo LLC
Inventor： Christian Michael Harding , Cory James Knoot
IPC: A61K39/108 , A61K47/64 , A61P31/04 , C07K14/26
CPC classification number: A61K39/0266 , A61K47/646 , A61P31/04 , C07K14/26 , A61K2039/6037
Abstract: Provided herein is a bioconjugate comprising a K. pneumoniae O-antigen covalently linked to a fusion protein comprising a ComP protein or a glycosylation tag fragment. The K. pneumoniae O-antigen bioconjugate of this disclosure can be used as a conjugate vaccine including multivalent conjugate vaccines comprising multiple K. pneumoniae O-antigens.
-
公开(公告)号：US11911451B2
公开(公告)日：2024-02-27
申请号：US16640988
申请日：2018-08-21
Applicant: ImmuLogix Ltd
Inventor： Richard Ascione , Shengmei Qi
CPC classification number: A61K39/0011 , A61K39/0016 , A61K39/0018 , A61K47/646 , A61P35/00 , A61K2039/6037
Abstract: The present invention relates to immunogens directed against lung cancer associated proliferative peptides and growth factors and its uses thereof in conjunction with chemotherapeutics in the early and advanced treatment of various malignant diseases, especially including lung cancers, both small cell lung carcinomas (SCLC), non-small cell lung (NSCLC) cancers and neuroendocrine-type cancers.
-
公开(公告)号：US11896656B2
公开(公告)日：2024-02-13
申请号：US17049266
申请日：2019-04-25
Applicant: Merck Sharp & Dohme LLC
Inventor： Patrick Leonard Ahl , Akhilesh Bhambhani , Christopher Jon Farrell , Patrick McHugh , Morrisa C. Jones , Daniel D. Roth , Jessica R. Sinacola , Justin Stanbro , Matthew P. Watson , Emily Wen , Michael A. Winters
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/6037
Abstract: A method is described for reconstituting lyophilized mutant diphtheria toxin in dimethyl sulfoxide for use in producing pneumococcal capsular polysaccharide mutant diphtheria toxin conjugates.
-
公开(公告)号：US11883478B2
公开(公告)日：2024-01-30
申请号：US14777985
申请日：2014-03-17
Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
Inventor： Yaela Baine , Jacqueline Miller
IPC: A61K39/095 , A61K39/102 , A61K39/00
CPC classification number: A61K39/095 , A61K39/102 , A61K2039/55 , A61K2039/6037 , A61K2039/70 , Y02A50/30
Abstract: The application discloses method of immunising against Neisseria meningitidis infection comprising the steps of a) immunising a human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a Neisseria meningitidis conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N. meningitidis serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein, wherein the Neisseria meningitidis conjugate vaccine is co-administered with a vaccine comprising diphtheria toxoid and tetanus toxoid.
-
-
-
-
-
-
-
-
-
Search Results
1529
records
(took 0.028 seconds)
